DOCSLIB.ORG

Day 1 Printable Slides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Herbal Smoking Blends - SPICE • SPICE and other herbal blends have been sold in head shops and on the Internet since 2006 for their cannabis-like intoxication Classes and Structures of Emerging Cannabimimetics • The herbal blends sometimes have a fragrance and Cathinones which could include vanilla, potpourri, spice, blueberry, caramel, and strawberry Arthur Berrier Senior Research Chemist Special Testing and Research Laboratory • The plant materials for the different blends Drug Enforcement Administration have a wide variation in appearance ~ ) D[A Speco0I Tornnr. oncl lle1ea1ch 1.1boratory ~~ Emt!•t;mg Trends Ptobr,1m Herbal Smoking Blends - SPICE Herbal Smoking Blends - SPICE • In late 2008, THC Pharma reported the • K2 enters market in April, 2009 presence of JWH 018, a synthetic cannabimimetic indole in some blends • Interest booms in herbal smoking blends in 2009 • In early 2009, analogues of CP 47,497 (another synthetic cannabinoid) were also • Many new products appeared, typically with found in some blends by the U. of Freiburg JWH 018 and JWH 073 • In early 2009, several European Countries • States begin to control the blends/synthetic control Herbal Blends/JWH 018/CP 47,497 cannabinoids ~) 0(1\ Spr•c:i.11 f~l'.. [1 ng and Rtl~C!'allh l11hor,1to ry ~ ' ) O(I' S1Jec1a l Tl.?sltng amJ RPWJr< h l .1bor,1tory r"::::> Fme rf;mg Trt>nd. Proc;f.101 ~=> [me1eing Tr!>nth P1ogr.i111 Classes of Synthetic Cannabinoids Herbal Smoking Blends - SPICE Observed on Smoking Blends • Products quickly reformulated with new, non­ i) 2-(3-hydroxycyclohexyl)phenol (CP 47,497) controlled synthetic cannabimimetics ii) 3-(1-naphthoyl)indole (JWH 018) iii) 3-(1-naphthoyl)pyrrole • Five of the synthetic cannabimimetics iv) 1-( 1-naphthylmethylene )indene controlled at the Federal level in 2011 v) 3-phenylacetylindole or 3-benzoylindole • Synthetic Drug Abuse Prevention Act of 2012 ~ ) 11[ •\ "' 1,r( 1,-,1 lf'.',..tr11g and [~p Pnrch lJUOrdto1 y ~ \ DE/\ Special Te1 1ing .1nrJ R·~>P<Hrh I abora\Clly r C :> f 1n~~ 1 ,_,1 r\ , Trc11ds P1L)grJm -r.:---::::>J fniPre1ng lrend'.. Progrom Structures o,f the Major Cannabimimetics Observed in 2009 and 2010 - Cannabimimetic Classes Detected First Appearance of JWH Compounds o:rd ~ <3-phenylacolyhndole J 3-11-nuphlhoyl)indole < JWH 203 > JWH 018 \ JWH018 JWH073 JWH 250 ~o CP 47,497 ? 3-beri zoy nllole ( RCS-4 2--{3-hydroxycyclohexyl)phenol CP 47 497 C8 ~ ' ) DtP Special le.::.L1ng an d Research Labor ,1to1 y ~ \ lJEA Sptcial Te,lmg und Re;ca1ch lauoratory r e> Fme1t;111b Tremh PrO!; ICJ!ll S,} f.mergrng lrt:'nd:; Program Cannabimimetics Observed Starting in 2011- More 2011- Introduction of Fluoroalkyl JWH's, Introduction of Fluoroalkyls and the Beginning of Novel Materials Derivatives JWH019 JWH 081 JWH 018 JWH 122 JWH 073 JWH 200 JWH250 AM 2201 CP 47,497 AM694 RCS-4 JWH 018 AM2201 RCS-8 Fluoro version of JWH 018 ~ \ O[A Spec1ul ie:.t1ng ,md Ri:'iearch I ubor(1tory ~ ' ) lJEA Spec1ol Te,t1ng ,1nd Research Laboratory ~-:::::>} r nlt:rbuig lr(•nd~ Progrl'n'1 .-::-c::> fme151ng Trends. Progrilm 2011- Introduction of Novel Materials 2011- Introduction of Novel Materials RCS-4 • Materials identified never reported in scientific or patent literature • Initially named after the website selling it = - RCS-4 - RCS-8 AM67Q RCS-4 JWH081 • Made by changing/modifying known material New ~ ') DI 1\ Special Te:;.t111g anU Re:evrch I il l>0ratorv ~ ',) DEA S1wr:1CJI T~ ~t1ng and Re_,ea1ch Laboratory S I mrrt~mg lr('rah ProgrJm f"'."C > Ernert,1ng T1 en d_, Pro1:11.1m 2011- Introduction of Novel Materials Cannabimimetics Observed Starting in 2012 - RCS-8 Continuation of New Materials and New Classes JWH 019 JWH203 JWH 081 UR 144 JWH 018 JWH 122 A 796,260 JWH 073 JWH200 5FUR144 JWH 250 AM 2201 2NE1 CP 47,497 AM694 STS-135 RCS-4 AKB48 RCS-8 ABOOl JWH 250 RCS-8 New ~ ·) DEA Special Te :.t 1ng and Re~earch LC1bor.lto1y ~ ') DEA Special Testing and Re, h i1rh L..ilioratory ~..::> I rner gmg T1 en ds. Progr a1n ~:> Emerging Trends P1ogrc1m 2012 - Introduction of AKB48 - New Material in 2012 Tetramethylcyclopropyl Materials 0 Ql ~J H cr;N ~ ~ = ~ 0 ~ ~ F ~ A-796.260 U R-14 4 5FUR 14 4 AKB48 A-It l abs A-It l abs New Falls within claims of 2003 World Patent but not given as example ~ ) OlA Special Te~t1ng a nd ke~C'arc h L.1 boratory ~ ~) DEA Special Te::.t111g and Re::.e2. rch l dborato1y ~? [ m er~ rn g T am d ~ Prog ram ;-:;~ E1ne1g111g T1 c nds Progrdm 2012 - Continued Introduction of New 2012 -ABOOl, A New Material Derived Materials from a Combination of Known Compounds ~ AM124B ~ l\K.848 2NE1 STS-135 'low lndole vt=rs1on of AK 940 H 10ro ver&on o( 2NE1 A8 001 New New -:~ JWH~ New ~ ) [JfA '"pf'c1al Te:.t1ng and Re~earch Lalwr ,1to1y ~ J Dfl\ ~pec1a l T<-1tin;: .ind He·.~aich UborJtory ~/ hnt·1 ~ 111 g Trend:. Progrcim r':::::> ( nwrg111g rrends Progr.1m Cannabimimetics Observed Starting in 2013 - 2013 - Introduction of lndazole Continuation of New Materials and New Classes Carboxamides and Derivatives +1111••111 JWH 019 JWH203 MN-25 JWH081 UR 144 AB-FUBINACA JWH018 JWH 122 A 796,260 ADB-FUBINACA = JWH073 JWH 200 5FUR144 PB22 JWH250 AM 2201 2NE1 5FP822 CP 47,497 AM 694 STS-135 8822 RCS-4 AK848 A8PINACA RCS-8 A8001 AD8/CA AB-FUBINACA AB-P!NACA 2009 Pfizer Patent New ~ J DEA Specral Test mg and Reoei1fch Lobo r ~tory ~) DEA Snec•ol Tes t on~ and Re , e,1'ch laborotory f':'Q lmer;;rng hend> Progr<1m S [mer~inc: Trends P1ogr.1m 2013 - Introduction of lndazole 2013 - New Materials Derived From Carboxamides and Derivatives 8-Hydroxyquinoline = = = c6·0tY c6°t9' c6°t9 ~ '-v ~ 88-22 PB-22 5Ff>S..22 New Now Ne~ Esler, Ouifl.uhne ADB-FUBINACA ADBICA 2009 P1izer Patent New ~ \ DEi\ Speual Te:.ting and Rt"'::iea1 ch Laboratory ~ ') DEA 5pccral ieslrng ,ind Re;e,lfch Labor,1tory "'':::::) Emerging T1encls Prog101T"\ S EnH~f t,; 1ng Trend1.. Progrom Designer Cathinones - Designer Cathi nones Changes in the Aromatic Ring Three parts of methcathinone can be modified: Aromatic ring O Alkyl group drH Amine group N'-.... C H3 ' motht111h nooe Armm1tic Alkyl Amine ~) DE1\ <;pecral Te'lrng and Reseorch I <1bor,1tory ~ " [1E1\ SpPcral Te,t111g ar'U RP~:,(?arch L;:iborator { S fmer1;111g Trrntl~ Prngr.1111 ~c:) Cme1 t:;ing T1 f'nd::. P1 r\~1 din Designer Cathinones - Designer Cathinones - Changes in the Alkyl Group Changes in the Amine Group 0 H ~, N-CH 3 O CH3 melhcathinone ethcathinone methcathinone buphedrone 0 H o I\ .,, )I ( N ,,/ '"'r-N 'CH3 ( O CH, ......,:.-· CH, methcathinone methcathinone r<-PPP ~ - ) Dfll Spc<.101 foiling'""' ReseMch l oboroto1y ~\ DEA 5peual Je;tmg and Resea1ch L.1bor,,101y ~ [me1r;11\G frt!tlcl!. ProgrJm ~.::::::>} f:merc,1ng Trends Progr,1m Designer Cathinones - Questions? Changes in All Groups methcathinone MDPV Arthur Berrier [email protected] Just the changes discussed in the last three slides can produce 12 different Cathinone derivatives Drug Enforcement Administration ~) Dfl\ Special Tes11ng onci Rese;;tr.h l.ilm<dlory ~ '\ DEA Spt>c1al feJll1\r; and Re_,earch Laboratory ~::::> fmere,1np, Trends Prngi.:im -, 2:..>) Eine1,;111~ T1enrb Pro~1J111 Outline • Hallucinogens • Plant-Derived Highs - 2C Compounds - Kratom - NBOMe Compounds - Fly Agaric Mushrooms Novel Hallucinogens and - DOX Compounds - Kava Kava - Kanna Plant-Derived Highs • Empathogens - Aminoindanes Emily Dye - APDB Forensic Chemist - APB Special Testing and Research Laboratory Drug Enforcement Administration ~) Drn ~peC1al Te;tmg and H,»earr.h 1.1bor.11ory ~ fmergrng Trends P1ug1um 2C Compounds 2C Compounds Name R1 I R1 • Psychedelic phenethylamines 2C-B H Br 2c-c• Cl 2c-o• H CH, 2C-E"' CH2CH1 2C-F 2C-T-2"' SCH10t, • Synthesized by Alexander Shulgin ZC-T-4" SCH(CH J, 2C-G CH1 CH, 1 - Published in PiHKAL 2C-G-3 (CH,), 2C-T-7 H S{CHzhCH, 2C-G-4 {CH2)4 2C-T-8 SCH 2CH (CH ih 2C-G-N (CH), 2C-T-9 H SC(CH1), 2C-H• H H 2C-T-13 H S(CH 2)20 CH, • 27 known compounds 2c-1• H 2C-T-15 H SCH(CH,J, 2C-N' H NO, 2C-T-17 SCH(CH l)CH2CH1 - Most common: 2C-C, 2C-B, and 2C-I 2C-O H OCH, 2C-T-21 H S(CH 2),F 2C-0-4 H OCH(CH 1J, 2C-TFM CF 2C-P"" H CH2CH2CHJ 1 ~\ DfA <; pec1al Test111g and Research Labor,1tn1v ~ ' ) DEA Special Testing and Re scdrch l dl.Joratory ~} frnerg1ng Trends Program ~J ErY1erg1ng Trench Progr<1m 2C-B-FLY Bromo-DragonFLY 0 CH ~ • Psychedelic phenethylamine • Psychedelic phenethylamine B IH2 0 • Synthesized by Aaron Monte • Synthesized in the lab of David Nichols • Deaths associated with misrepresentation as 2C-B-FLY ~~ ' ) Uri\ Special Testing <ln d Resea1ch Laboratory ~., ' ) DEA SJ> ec1al Testing anci Re~ e arch I aboratory ~_:> [111prg1ng Trends P1 og1 .Jm ~:.:> Eme1 gmg Ti ends Program Mti,.IMKllCM+M-CMM@l,,IWW·'MWWW NBOMe Compounds 258-NB20Me Br OCHJ H H 25N-NB20Me N01 OCH 1 H H 25B -NB30Me Br H OCH1 25N-NB30Me NO, OCH 3 25B-NB40Me Br H OCH1 25N-NB40Me NO, H OCH 1 25C-NB20Me Cl OCH 3 H 2SP-NB20Me CH 2CH 2CH 3 OCH3 • Hallucinogenic phenethylamines 25C-N830Me Cl OCH 1 25P-NB30Me CH;i,CH1CH1 OCH1 H 25C-NB40Me Cl OCH 3 25P-NB40Me CH 2CH 2CH 3 H OCH3 25D-NB20Me CH, OCH1 H 2ST2-NB20Me CH,CH,S OCH, H 25D-NB30Me CH, H OCH3 25T2-NB30Me CH 3CH 2S OCH1 25D-NB40Me ,, ,_y.· CH, OCH, 25T2-NB40Me CH3CH,S H H OCH 1 25E-NB20Me C2Hs OCH 3 H 25T4-NB20Me (CH3 JiCH5 OCHl H • Synthesized by Heim, et al .
Recommended publications
  • FSI-D-16-00226R1 Title

    FSI-D-16-00226R1 Title

    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra

    Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra

    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
  • From Sacred Plants to Psychotherapy

    From Sacred Plants to Psychotherapy

    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test

    Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test

    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
  • Synthetic Drugs: Overview and Issues for Congress

    Synthetic Drugs: Overview and Issues for Congress

    Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013.
  • Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and Updated)

    Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and Updated)

    Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. Mention of names of firms and commercial products does not imply theendorsement of the United Nations. ST/NAR/48/REV.1 © United Nations, July 2020. All rights reserved, worldwide The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Services of the United Nations Office on Drugs and Crime (UNODC) (LSS, headed by Dr.
  • Neuroreceptor Activation by Vibration-Assisted Tunneling

    Neuroreceptor Activation by Vibration-Assisted Tunneling

    OPEN Neuroreceptor Activation by SUBJECT AREAS: Vibration-Assisted Tunneling BIOPHYSICAL CHEMISTRY Ross D. Hoehn1, David Nichols2, Hartmut Neven3 & Sabre Kais4,5,6 MECHANISM OF ACTION 1Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA, 2Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA,3 Google, Venice, CA 90291, USA,4 Department of Received 5 20 October 2014 Chemistry, Purdue University, West Lafayette, IN 47907, USA, Departments of Physics, Purdue University, West Lafayette, IN 47907, USA,6 Qatar Environment and Energy Research Institute, Qatar Foundation, Doha, Qatar. Accepted 20 March 2015 G protein-coupled receptors (GPCRs) constitute a large family of receptor proteins that sense molecular Published signals on the exterior of a cell and activate signal transduction pathways within the cell. Modeling how an 24 April 2015 agonist activates such a receptor is fundamental for an understanding of a wide variety of physiological processes and it is of tremendous value for pharmacology and drug design. Inelastic electron tunneling spectroscopy (IETS) has been proposed as a model for the mechanism by which olfactory GPCRs are activated by a bound agonist. We apply this hyothesis to GPCRs within the mammalian nervous system Correspondence and using quantum chemical modeling. We found that non-endogenous agonists of the serotonin receptor share requests for materials a particular IET spectral aspect both amongst each other and with the serotonin molecule: a peak whose should be addressed to intensity scales with the known agonist potencies. We propose an experiential validation of this model by S.K. (kais@purdue. utilizing lysergic acid dimethylamide (DAM-57), an ergot derivative, and its deuterated isotopologues; we also provide theoretical predictions for comparison to experiment.
  • Immediate Action New Tests and Test Updates

    Immediate Action New Tests and Test Updates

    Effective Date: Monday, August 26, 2013 New Tests and Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, August 26, 2013 New Tests - Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue
  • The Renaissance in Psychedelic Research: What Do Preclinical Models Have 2 to Offer

    The Renaissance in Psychedelic Research: What Do Preclinical Models Have 2 to Offer

    CHAPTER The renaissance in psychedelic research: What do preclinical models have 2 to offer Kevin S. Murnane1 Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, United States 1Corresponding author: Tel.: +1-678-547-6290; Fax: +1-678-547-6423, e-mail address: [email protected] Abstract Human research with psychedelics is making groundbreaking discoveries. Psychedelics mod- ify enduring elements of personality and seemingly reduce anxiety, depression, and substance dependence in small but well-designed clinical studies. Psychedelics are advancing through pharmaceutical regulatory systems, and neuroimaging studies have related their extraordinary effects to select brain networks. This field is making significant basic science and translational discoveries, yet preclinical studies have lagged this renaissance in human psychedelic research. Preclinical studies have a lot to offer psychedelic research as they afford tight control of experimental parameters, subjects with documented drug histories, and the capacity to elucidate relevant signaling cascades as well as conduct invasive mechanistic studies of neurochemistry and neural circuits. Safety pharmacology, novel biomarkers, and pharmaco- kinetics can be assessed in disease state models to advance psychedelics toward clinical practice. This chapter documents the current status of psychedelic research, with the thematic argument that new preclinical studies would benefit this field. Keywords Psychedelic, Preclinical, Serotonin, Neuroimaging, Alcoholism, Anxiety, Depression, Substance dependence 1 INTRODUCTION The term psychedelic has come to be associated with a broad class of drugs with diverse chemical, pharmacological, and psychoactive effects. Alternative nomencla- tures have used hallucinogen, entheogen, psychotomimetic and other appellations to Progress in Brain Research, Volume 242, ISSN 0079-6123, https://doi.org/10.1016/bs.pbr.2018.08.003 25 © 2018 Elsevier B.V.
  • Temporary Class Drug Order Report: 5-6APB and Nbome Compounds

    Temporary Class Drug Order Report: 5-6APB and Nbome Compounds

    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives.
  • Synthetic Cannabinoids Synthetic Cannabinoids-1

    Synthetic Cannabinoids Synthetic Cannabinoids-1

    Synthetic Cannabinoids-1 Synthetic Cannabinoids ™ (HEIA ) For the detection of JWH-018, JWH-073, AM-2201 & their major metabolites Homogeneous Enzyme Immunoassay (HEIA™) K2-3 K2-2 K2-1 Assay Specifications Sensitivity: 100% LC-MS/MS Confirmation Specificity: 87.5% Methodology: Homogeneous Enzyme Immunoassay Accuracy: 96.9% Positive Negative Cutoff: 10 ng/mL HEIA Positive 48 2* Calibrator: JWH-018 N-pentanoic acid (10 ng/mL) Negative 0 14 *2 discrepant specimens that screened negative were borderline negative at 10 ng/mL cutoff. AB-PINACA ADB-PINACA UR-144 XLR11 JWH-018 JWH-073 AM-2201 Immunalysis now offers three distinct Synthetic Cannabinoid Homogeneous Enzyme Immunoassays (HEIA™) Cross-Reactivity N/D = Cross-Reactivity < 0.05% for the detection of Synthetic Cannabinoids in urine. Our assays, geared towards the detection of JWH-018, JWH-073, AM-2201, UR-144, XLR11 and their metabolites, are now complemented by a NEW assay targeted Analyte Analyte Concentration JWH-018 N-pentanoic acid Cross-Reactivity at the next generation, AB-PINACA and ADB-PINACA compounds found in the current Spice or K2 products. (ng/mL) Equivalent (ng/mL) (%) Together, these assays detect Schedule I controlled substances and provide the most comprehensive screening JWH-018 N-pentanoic acid 10 10 100 tool for your automated chemistry analyzer. JWH-018 N-(5-hydroxypentyl) 15 10 67 JWH-018 4-hydroxyindole 135 10 7.4 JWH-018 5-hydroxyindole 40 10 25 AM-2201 N-(4-hydroxypentyl) 12 10 83 Liquid Stable, Ready to Use AM-2201 6-hydroxyindole 20 10 50 JWH-073 N-(4-hydroxybutyl)